TP53 and acute myeloid leukemia: Though the 2022 ICC defined AML with MDS-R gene mutations exclude those with TP53 mutations [9, 10], we included all patients with MDS-R mutations regardless of the presence or absence of TP53 mutations since the aim of this study was to evaluate the clinical relevance and prognostic impact of MDS-R mutations in AML as that was done in the study of Lindsley et al. [7].